Advertisement

Preclinical Testing of New Drugs the CPMP Guidelines as a Model for International Harmonisation

  • J. P. Griffin
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 39)

Abstract

In this time of escalating costs there is a compelling need to minimize the costs in time, money and valuable resources spent on preclinical evaluation of new drugs. International harmonisation of requirements is a major step in this direction.

Keywords

Drug Substance Safety Evaluation Working Party Mutagenicity Test Toxicological Evaluation 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Draper M F and Griffin J P (1980) Draft CPMP Guidelines on Mutagenicity Testing. Arch Toxicol (in press)Google Scholar

Copyright information

© Springer Science+Business Media New York 1981

Authors and Affiliations

  • J. P. Griffin
    • 1
  1. 1.Department of Health & Social SecurityMarket TowersLondonUK

Personalised recommendations